Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Expands Consumer Business With Acquisition Of OTC Cold Sore Products

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline further expands its rapidly growing consumer health care business by acquiring exclusive marketing rights to two cold sore treatments in a week, just months after announcing a third deal in the category
Advertisement

Related Content

Meda Lands In U.S. OTC Space With Alaven Buy
Meda Lands In U.S. OTC Space With Alaven Buy
Meda Lands In U.S. OTC Space With Alaven Buy
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
GSK Pursues Futura Medical's OTC Topical NSAID Under Development
GSK's Launches, Global Expansion Drive Consumer Sales Ahead Of Market
NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS104249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel